RBC Capital raised the firm’s price target on Teleflex to $272 from $228 and keeps an Outperform rating on the shares after meeting with its senior management team. The company is focused on execution and delivering ‘durable growth’ against the backdrop of positive healthcare utilization trends, the analyst tells investors in a research note. RBC adds that its increased price target reflects the recent run-up in the stock price and the current peer multiples.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TFX:
- Teleflex now offers its Titan SGS™ Stapler with Staple Line Reinforcement
- Teleflex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Teleflex price target raised to $270 from $221 at Truist
- Teleflex price target raised to $265 from $225 at Wells Fargo
- These 2 MedTech Stocks Look Too Cheap to Ignore, Says Morgan Stanley
